About Generex Biotechnology
Generex Biotechnology is a publicly listed company based in Miramar (United States) founded in 1983. Technologies for large molecule drug delivery are developed. The company has 5 employees. Generex Biotechnology has completed 6 acquisitions, including Altucell, Antigen Express and Emmaus Medical. Its focus areas include Life Sciences, Diabetes and Drugs. Its legal entity is GENEREX BIOTECHNOLOGY CORP. Similar companies include Sana Biotechnology, Semma Therapeutics and Rezolute; 2 of its 3 listed similar companies have raised funding.
Company details
Generex Biotechnology was founded in 1983 in Miramar, United States, within the biotechnology sector. Focus is placed on proprietary drug delivery technologies, including the RapidMist device for buccal administration of drugs via the mouths inner lining. Operations center on products such as Generex Oral-lyn, a buccal insulin spray, targeting metabolic and immunological diseases through non-invasive methods.
- Headquarters Miramar, United States
- Employees 5
- Stage Public
- SectorsHealthcare
- Email••••••••
- Website generex.com
- Social LinkedIn X Facebook
- Legal Name Generex Biotechnology Corp
- Latest Funding Round$2M (USD), Post-IPO
Aug 2020
- Employee Count5
- Investments & AcquisitionsAltucell
& 5 more
Funding Insights of Generex Biotechnology
- Total Rounds 6
- Last Round Post-IPO — $2M
- First Round $3M
(Jan 2011)
All 6 funding rounds of Generex Biotechnology with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2020 | $2M | Post-IPO | – | – | – |
| Dec 2019 | $2.2M | Post-IPO | – | – | – |
| Aug 2012 | $750,000 | Post-IPO | – | – | – |
| Feb 2012 | $2M | Post-IPO | – | – | – |
| Jan 2012 | $3.6M | Debt – Conventional | – | – | – |
| Jan 2011 | $3M | Post-IPO | – | – | – |
People of Generex Biotechnology
12 people are tracked at Generex Biotechnology (6 in leadership, 5 in board & advisors, 1 in team); the tracked headcount is 5.
| Name | Role | Group |
|---|---|---|
Anthony S. Crisci | Chief Legal Officer & Chief Administrative Officer | Leadership |
Andrew Ro | Chief Investment Officer & Director | Leadership |
Dr. David Brusegard | Chief Operating Officer | Leadership |
Jason B. Terrell | CSO & Chief Medical Officer | Leadership |
Terry Thompson | Chief Operating Officer | Leadership |
Mark Corrao | CFO & Treasurer | Leadership |
James H. Anderson | Independent Director | Board & advisors |
Brian T. McGee | Independent Director | Board & advisors |
Lawrence Salvo | Director | Board & advisors |
Mark Prioletti | Independent Director | Board & advisors |
Craig Eagle | Independent Director | Board & advisors |
Artyom Tom Tshughuryan | Shareholder | Team |
Complete people profiles for Generex Biotechnology
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Generex Biotechnology
Generex Biotechnology has strategically engaged in corporate development activities, having acquired 6 companies. Notable acquisitions include Altucell, Antigen Express and Emmaus Medical.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Regenerative therapies for neurodegenerative and autoimmune diseases are developed. | altucell.com | Babylon, United States | 2010 | Sep 2019 | •••• | |
| medisourcepartners.com | 0 | Jul 2019 | •••• | |||
Regenerative medicines for gastrointestinal disorders are developed. | regentys.com | Miami, United States | 2009 | Jan 2019 | $15M | |
IVDs for infectious diseases in developing nations are developed. | rapid123.com | Miramar, United States | 2000 | Dec 2018 | •••• | |
Emmaus Medical is engaged in developing treatments for rare diseases. | emmausmedical.com | Torrance, United States | 2000 | Jan 2017 | •••• | |
Antigen-specific immune modulation for cancers and autoimmune diseases is developed. | antigenexpress.com | Wellesley, United States | 1993 | Jun 2003 | •••• |
Complete acquisition details for Generex Biotechnology
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Generex Biotechnology
10 dated milestones of Generex Biotechnology across 37 years, from founding to its latest funding, stage changes and deals.
- Founded Generex Biotechnology is founded.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Antigen Express.
- Funding First funding round of $3.0M.
- Acquisition Acquires Emmaus Medical.
- Acquisition Acquires HEMA Diagnostic Systems.
- Acquisition Acquires Regentys.
- Acquisition Acquires Medisourcepartners.
- Acquisition Acquires Altucell.
- Funding Latest funding round, Post-IPO, of $2.0M.
Similar companies to Generex Biotechnology
Generex Biotechnology has 3 listed similar companies in our database, 2 of them funded. They include Sana Biotechnology, Semma Therapeutics and Rezolute.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| sana.com | 2018 | Seattle, United States | $821M | 328 | Genetically engineered cell therapies are developed for multiple disorders. | |
| semma-tx.com | 2015 | Cambridge, United States | $158M | 58 | Provider of bio-artificial pancreas for Type 1 Diabetes treatment | |
| rezolutebio.com | 2012 | Denver, United States | 51 | Therapies for metabolic and orphan diseases are developed by Rezolute. |
Detailed similar companies of Generex Biotechnology
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Diabetes
3 companies that operate in the same segment as Generex Biotechnology (Diabetes) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of devices for continuous glucose monitoring and manual insulin delivery | 2008 | San Diego, California, United States | USD 100.73 M | USD 1.02 B | 2,650 | |
Wearable glucose monitoring patches are provided for real-time data tracking. | 1999 | San Diego, California, United States | USD 52.5 M | USD 4.66 B | 10,300 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Generex Biotechnology
Complete news archive for Generex Biotechnology
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Generex Biotechnology
Generex Biotechnology was founded in 1983 and raised its 1st funding round 28 years after it was founded.
Generex Biotechnology is headquartered in Miramar, United States. It is registered at Miramar, Florida, United States.
Generex Biotechnology has 5 employees.
Generex Biotechnology was founded in 1983 in Miramar, United States, within the biotechnology sector. Focus is placed on proprietary drug delivery technologies, including the RapidMist device for buccal administration of drugs via the mouths inner lining. Operations center on products such as Generex Oral-lyn, a buccal insulin spray, targeting metabolic and immunological diseases through non-invasive methods.
Generex Biotechnology's top competitors include Sana Biotechnology, Semma Therapeutics and Rezolute.
Generex Biotechnology has made 6 acquisitions, including Altucell, Antigen Express, and Emmaus Medical.
Generex Biotechnology operates through Generex Biotechnology Corp.